TEZSPIRE (tezepelumab-ekko)
ASTHMA THERAPY - THYMIC STROMAL LYMPHOPOIETIN INHIBITOR, MAB · CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS ·+1
AMGEN
Drug class
Asthma Therapy - Thymic Stromal Lymphopoietin Inhibitor, MAb
The drug class "Asthma Therapy - Thymic Stromal Lymphopoietin Inhibitor, MAb" represents a specialized compendial and clinical category of biologic agents designed to treat severe respiratory conditions by targeting upstream airway inflammation. Read more about Asthma Therapy - Thymic Stromal Lymphopoietin Inhibitor, MAb
1 drugs in this class 1 manufacturers
Drugs in Asthma Therapy - Thymic Stromal Lymphopoietin Inhibitor, MAb
Filter & compare in the drug finder →
Opens the drug finder with Asthma Therapy - Thymic Stromal Lymphopoietin Inhibitor, MAb preselected. Add indication or manufacturer filters there.
The drug class "Asthma Therapy - Thymic Stromal Lymphopoietin Inhibitor, MAb" represents a specialized compendial and clinical category of biologic agents designed to treat severe respiratory conditions by targeting upstream airway inflammation.
Monoclonal antibodies in this class bind selectively to thymic stromal lymphopoietin, an epithelial cell–derived cytokine that functions as an alarmin at the apex of multiple inflammatory cascades, preventing its interaction with heterodimeric receptor complexes.
This inhibition interrupts downstream allergic, eosinophilic, and non-eosinophilic inflammatory signaling pathways without requiring specific phenotypic or biomarker restrictions.
Represented by agents such as tezepelumab, the class is primarily indicated as an add-on maintenance therapy for severe asthma and related upper airway disorders like chronic rhinosinusitis with nasal polyps.
-
delveinsight.com
The drug class "Asthma Therapy - Thymic Stromal Lymphopoietin Inhibitor, MAb" represents a specialized compendial and clinical category of biologic agents designed to treat severe respiratory conditions by targeting upstream airway inflammation Monoclonal antibodies in this class bind selectively to thymic stromal lymphopoietin, an epithelial cell–derived cytokine that functions as an alarmin at the apex of multiple inflammatory cascades, preventing its interaction with heterodimeric receptor co...
-
fda.gov
The drug class "Asthma Therapy - Thymic Stromal Lymphopoietin Inhibitor, MAb" represents a specialized compendial and clinical category of biologic agents designed to treat severe respiratory conditions by targeting upstream airway inflammation Monoclonal antibodies in this class bind selectively to thymic stromal lymphopoietin, an epithelial cell–derived cytokine that functions as an alarmin at the apex of multiple inflammatory cascades, preventing its interaction with heterodimeric receptor co...
-
nih.gov
Monoclonal antibodies in this class bind selectively to thymic stromal lymphopoietin, an epithelial cell–derived cytokine that functions as an alarmin at the apex of multiple inflammatory cascades, preventing its interaction with heterodimeric receptor complexes
-
youtube.com
This inhibition interrupts downstream allergic, eosinophilic, and non-eosinophilic inflammatory signaling pathways without requiring specific phenotypic or biomarker restrictions
-
nih.gov
This inhibition interrupts downstream allergic, eosinophilic, and non-eosinophilic inflammatory signaling pathways without requiring specific phenotypic or biomarker restrictions Represented by agents such as tezepelumab, the class is primarily indicated as an add-on maintenance therapy for severe asthma and related upper airway disorders like chronic rhinosinusitis with nasal polyps
-
fda.gov
Represented by agents such as tezepelumab, the class is primarily indicated as an add-on maintenance therapy for severe asthma and related upper airway disorders like chronic rhinosinusitis with nasal polyps
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.